Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study.
Karim Sultan HaiderAhmad HaiderFarid SaadGheorghe DorosMarkolf HanefeldSandeep DhindsaParesh DandonaAbdulmaged TraishPublished in: Diabetes, obesity & metabolism (2020)
Long-term TTh in men with T2DM and hypogonadism improves glycaemic control and insulin resistance. Remission of diabetes occurred in one-third of the patients. TTh is potentially a novel additional therapy for men with T2DM and hypogonadism.
Keyphrases
- type diabetes
- glycemic control
- replacement therapy
- insulin resistance
- cardiovascular disease
- end stage renal disease
- newly diagnosed
- smoking cessation
- middle aged
- disease activity
- metabolic syndrome
- ulcerative colitis
- skeletal muscle
- peritoneal dialysis
- rheumatoid arthritis
- electronic health record
- machine learning
- combination therapy
- patient reported